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A 58-year-old Japanese woman complained of a painful right maxillary premolar gingiva and ulcer. ,e patient had RA and had
been treated with several immunosuppressive drugs such as methotrexate. Head and neck CT indicated no obvious bone de-
struction with maxillary. However, chest CT indicated the presence of nodular mass of the bilateral lungs. FDG-PET/CT indicated
the presence of increased uptake in both lesions. On immunohistochemistry, atypical large-sized lymphocytes were positive for
CD20 and EBER-ISH and negative for CD3, CD5, and CD10; the Ki-67 labeling index was high, the histopathological diagnosis
was EBV-positive DLBCL, and the clinical diagnosis wasMTX-LPD.,e patient’s treatment withMTXwas then discontinued; we
removed the alveolar bone which necrosed after 5 weeks. ,e lesion and the nodular mass at the bilateral lungs had completely
disappeared after 7 weeks.
1. Introduction
Methotrexate (MTX) is an anchor drug used to treat rheu-
matoid arthritis (RA), and several cases of the occurrence of
MTX-associated lymphoproliferative disorder (MTX-LPD)
have been reported [1]. According to the World Health Or-
ganization (WHO) Classification, MTX-LPD is classified as an
“other iatrogenic immunodeficiency-associated lymphoproli-
ferative disorder” [2]. Of the reported cases of patients diag-
nosed with MTX-LPD, 40%–50% have been extranodal,
occurring at sites of thoracicoabdominal organs. MTX-LPD
occurs at sites in the oral cavity such as the gingiva, tongue, and
mouth floor, but such cases are rare [2]. A case of a subtype of
MTX-LPD, i.e., Epstein–Barr virus- (EBV-) positive muco-
cutaneous ulcer (EBV-MCU)was reported, but there have been
very few comparisons of MTX-LPD and EBV-MCU in the oral
region. Here, we report an extremely rare case of a patient with
RA who developed MTX-LPD in the maxillary gingiva and
bilateral lungs, and we compare EBV-MCU and MTX-LPD.
2. Case Report
,e patient was a 58-year-old Japanese woman who visited
the Department of Dentistry and Oral Surgery, Tsuyama
Central Hospital (Okayama, Japan) at the end of May 2018,
complaining of a painful right maxillary premolar gingiva
and ulcer for the most recent 2 weeks. ,e patient had had
RA for 10 years and had been treated with several immu-
nosuppressive drugs, including MTX (2mg/week for 6
months and 4mg/week for 6 months) and prednisolone
(PSL: 2mg/week for 10 years).
On clinical examination, a right submandibular
lymph node was swollen, with pain. ,e intraoral ex-
amination showed swelling with necrotic ulcer formation
of the right maxillary gingiva in the canine to the first
molar region. ,ere was no exposure of perilesional al-
veolar bone. ,e perilesional premolar showed mild
mobility with occlusal and percussion pain (Figure 1(a)).
A blood examination revealed EBV infection (EBV viral
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capsid antigen IgG � 320, IgM < 10, IgA < 10, and EBV
nuclear antigen � 80).
,ere was no obvious bone destruction with lesion
anywhere as shown by dental radiographs and head and
neck computed tomography (CT). Lymph node swellings
were not detected except for the right submandibular lymph
node. However, chest CT indicated the presence of a nodular
mass that was suspected to be a malignant lung tumor of the
bilateral lungs, and S8 of the inferior lobe of the right lung
was the largest. Fluorodeoxyglucose-positron emission to-
mography/CT (FDG-PET/CT) indicated the presence of
increased uptake in the right maxilla (maximum stan-
dardized uptake value: SUVmax� 5.85) and bilateral lungs
(S8 of the inferior lobe of the right lung SUVmax� 4.94) but
no uptake in the right submandibular lymph node
(Figure 1(b)).
We performed a biopsy based on a suspicion of MTX-
LPD since the patient had been treated withMTX to treat RA
for approximately one year. Hematoxylin and eosin staining
showed a high degree of atypical large-sized lymphocyte
infiltration with a background of inflammatory cell infil-
tration in the submucosal stroma. Immunohistochemistry
staining showed that the atypical large-sized lymphocytes
were positive for CD20 and negative for CD3, CD5, and
CD10; the Ki-67 labeling index was high. ,e result of EBV-
encoded small RNA in situ hybridization (EBER-ISH) was
positive, and the histopathological diagnosis was EBV-
positive diffuse large B-cell lymphoma (DLBCL) (Figure 2).
It was not possible to make a diagnosis of bilateral lung
lesions because the patient refused an endoscopic biopsy, but
a hematologist and respiratory medicine physician at an-
other hospital indicated that the lung lesion was also MTX-
LPD. From the results obtained in these examinations, we
diagnosed MTX-LPD that had developed ectopically and
was expressed at the same time in the maxillary gingiva and
bilateral lungs.
We consulted the patient’s primary physician, and the
patient’s treatment with MTX was then discontinued. Two
weeks after the discontinuation of MTX, the ulcer and
swelling in the gingival lesion were reduced, and the swelling
and pain in the right submandibular lymph node had
resolved.
,e size of the nodular mass at the bilateral lungs also
began to reduce. At 4 weeks after the discontinuation of
MTX, we confirmed that the ulcer had disappeared com-
pletely, but the perilesional alveolar bone was exposed due to
shedding of the necrotic gingiva. At 5 weeks, the exposed
alveolar bone necrosed, and we removed sequestrum along
with the premolar of the patient under local anesthesia.
At 2 weeks after this surgery, the wound was covered by
normal epithelium, and the lesion had completely dis-
appeared. ,e nodular mass at the bilateral lungs had also
completely disappeared. ,e patient’s RA had slightly
worsened with joint pain, but her rheumatologist main-
tained good control of the symptoms with analgesics without
a change to another drug for RA. At 15 months since the
withdrawal of MTX, the patient was in a good condition
without recurrence.
3. Discussion
In 1991, Ellman et al. first reported MTX-LPD as a type of
malignant lymphoma that develops in patients with RA [3].
Lymphoproliferative disorders (LPDs) can develop in in-
dividuals with an autoimmune disease who are treated with
immunosuppressive therapy. It was also reported that RA
patients in particular are at an increased risk of developing
LPDs due to their RA itself, regardless of the presence/ab-
sence of immunosuppressive therapy [4]. Accordingly, pa-
tients with an autoimmune disease that is being treated with
immunosuppressive therapy are suspected to be at risk for
LPDs, but it is less well understood how MTX-LPD is di-
rectly related to iatrogenic immunosuppression.
MTX-LPD has been reported to occur in various parts of
the body, and recently the number of MTX-LPD cases in the
oral cavity has increased. However, our review of the re-
ported MTX-LPD cases leads us to note that the clinical
features and pathological conditions differ significantly
between the MTX-LPD that developed in the oral cavity and
the MTX-LPD that developed at other body sites. Table 1
summarizes the results of our review of the 51 reported cases
of MTX-LPD in the oral cavity (including our patient’s case)
in comparison with the reported MTX-LPD cases at other
body sites (n� 84) (Table 1).
(a) (b)
Figure 1: (a) Intraoral photograph: a painful necrotic ulcer in the right maxillary gingiva. (b) Horizontal FDG-PET/CT: pathological uptake
of FDG at the bilateral lung.
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,e average age of the patients with MTX-LPD in the
oral cavity is 70.2 years (range 40–87 years), and themale-to-
female ratio is 1 : 2.64, revealing a tendency toward females.
In addition, 98.0% of these patients were treated with a low-
dose MTX for RA; the average period from the diagnosis of
RA was 142.8 months (range 6–396 months), and the du-
ration of MTX treatment was 99.0 months (range 1–360
months).
Compared to the cases of MTX-LPD at other body sites,
there were almost no differences in age or the male-to-fe-
male ratio, but the period from the diagnosis of RA (37.3
months) and the duration of MTX treatment (42.3 months)
were much longer in the cases of MTX-LPD in the oral
cavity.
We next examined the ectopic cases of MTX-LPD
corresponding to Stages 2–4 in the Ann Arbor classification,
and we observed that the number of cases in the oral cavity
was significantly lower than the number in the rest of the
body (21.6% vs. 83.3%, x2(1)� 53.75, p< 0.01). ,e reoc-
currence rate was also significantly lower in the oral cavity
compared to the rest of the body (3.9% vs. 21.6%, x2(1)�
7.26, p< 0.01). Conversely, the EBV infection rate was
significantly higher in the oral cavity than in the rest of the
body (96.1% vs. 29.8%, x2(1)� 52.74, p< 0.01). Our com-
parison of these two patient groups thus revealed that re-
garding the occurrence of MTX-LPD, there are several
important differences between the oral cavity and the rest of
the body. To further investigate this issue, we also investi-
gated whether EBV-MCU might be a subtype of MTX-LPD.
EBV-MCU is an ulcer in a cutaneous or mucosal site. In
2010, Dojcinov proposed that EBV-MCU occurs in patients
with age-related or iatrogenic immunosuppression, and in
2016, EBV-MCU was newly added to the WHO Classifi-
cation of Tumors of Haematopoietic and Lymphoid Tissues
[5, 6]. EBV-MCU is defined as a B-cell lymphoproliferative
disorder that is associated with defective surveillance for
EBV and that frequently occurs in the oral mucosa, espe-
cially the gingiva; however, the pathogenesis of EBV-MCU is
not yet known, in part because there have been so few re-
ports [5, 7].
EBV infects >90% of world’s population and usually
continues to be suppressed by cell-mediated immunity after
the primary infection. However, it is reported that EBV
activation by some types of stimulation such as immuno-
suppression causes various diseases, including nasopha-
ryngeal cancer. Certain immunosuppressants further
promote EBV activation. MTX treatment was reported to
activate the EBV immediate-early promoters and promote
EBV replication [7–9].
EBV-MCU usually presents at a site that is subjected to
many chronic stimuli (e.g., the oral cavity, skin, and gas-
trointestinal tract) [5]. ,e oral cavity has many chronic
(a) (b)
(c) (d)
Figure 2: Histopathology results. ,e histopathological diagnosis was EBV-positive diffuse large B-cell lymphoma (DLBCL). (a) H&E stain
(×40) showed large numbers of lymphocytes accumulation in the submucosal stroma. (b) H&E stain (×200): lymphocytes accumulation was
atypical and large sized with a background of inflammatory cell infiltration. Immunohistochemistry stain (×200): tumor cells showed strong
positivity for CD20 (c) and EBER-ISH (d).
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stimuli; examples include periodontal disease and ill-fitting
dentures, which cause a local proliferation of EBV-infected
B cells [10]. ,ere are many EBVs in the saliva, gingival
crevicular fluid, and gingival tissue of patients with peri-
odontal disease. Imai et al. reported that the anaerobe Gram-
negative periodontal bacterium Phorphyromonas gingivalis
induces EBV activation [11]. ,e causes of EBV-MCU are
still unknown; however, we speculate that chronic irritation
owing to periodontal disease and poor denture stability are
related with the occurrence of EBV-MCU in MTX-treated
patients.
Age-related EBV-MCU due to immunosuppression is
difficult to treat, but EBV-MCU due to immunosuppressive
treatment can have a benign course with the withdrawal of
an immunosuppressive drug such as MTX. Even if the lesion
does not improve, chemotherapy works extremely well for
EBV-MCU. It was reported that 96.6% of patients with EBV-
MCU attain a complete remission, and there is no reported
death due to this disease [12].
MTX-LPD reported in the oral cavity is thus highly likely
to be EBV-MCU since the reported cases of MTX-LPD in
the oral cavity showed a high local EBV infection rate, few
ectopic cases, and good prognoses compared to MTX-LPD
at other sites in the body. However, this is only our spec-
ulation, as there is no definitive evidence for this. In our
patient’s case, we diagnosed MTX-LPD because lesions also
occurred in the lungs, but we also considered the possibility
of EBV-MCU. EBV-MCU is a subtype of MTX-LPD, but
there are still many points to consider before this disease
entity is fully explained. A further accumulation of cases and
analyses are necessary to establish the entire clinical picture
and condition, including the histopathologic features of
MTX-LPD and EBV-MCU.
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